Form4insider filings, from the source

SEC Form 4 · accession 0000903423-18-000561

Allogene Therapeutics, Inc. · ALLO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners
David Bonderman
Director · 10% Owner
Period of report
Oct 15, 2018
Accepted (ET)
Oct 17, 2018 · 5:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001737287

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F2,F3,F5,F6Oct 15, 2018C22,460,061$0.00A22,460,061ISee Explanation of Responses
Common StockF4,F1,F2,F5,F6Oct 15, 2018P675,000$18.00A23,135,061ISee Explanation of Responses

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Series A Preferred StockF1,F2,F3,F5,F6—Oct 15, 2018C4,278,107D——Common Stock22,460,0610I

Explanation of responses

Remarks

(7) The Reporting Persons are jointly filing this Form 4 pursuant to Rule 16a-3(j) under the Exchange Act. (8) Bradford Berenson is signing on behalf of both Messrs. Bonderman and Coulter pursuant to the authorization and designation letters dated March 13, 2018, which were previously filed with the Securities and Exchange Commission.